中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
105-107
,共3页
初发甲状腺%甲状腺功能%桥本甲状腺炎%疏肝散结方
初髮甲狀腺%甲狀腺功能%橋本甲狀腺炎%疏肝散結方
초발갑상선%갑상선공능%교본갑상선염%소간산결방
primary thyroid%thyroid function%Hashimoto''s thyroiditis%Shugan Sanjie Prescription
目的 探讨疏肝散结方治疗初发甲状腺功能正常桥本甲状腺炎(HT)的临床疗效.方法 选取初发甲状腺功能正常 HT患者108例,按随机数字表法分为试验组和对照组,各54例.对照组患者给予安慰剂治疗,试验组患者给予疏肝散结方中药治疗.结果 两组患者用药后甲状腺激素促甲状腺激素( TSH )、游离甲状腺素( FT4 )、游离三碘甲状腺原氨酸( FT3 )的含量与用药前相比,差异无统计学意义( P>0. 05);试验组患者的促甲状腺受体抗体( TRAb )含量为(0. 78 ± 0. 26)U/mL、抗甲状腺球蛋白抗体( TGAb )为(259. 69 ± 84. 73)U/mL、抗甲状腺过氧化物酶抗体( TPOAb )为(217. 67 ± 72. 45)U/mL,均明显优于对照组患者的(1. 93 ± 0. 45)U/mL、(406. 34 ± 125. 65)U/mL和(365. 23 ± 101. 74)U/mL( P<0. 05 );试验组患者的有效率为70. 37%,显著优于对照组患者的35. 19%( P<0. 05).结论 疏肝散结方治疗初发甲状腺功能正常HT患者效果显著,值得临床推广.
目的 探討疏肝散結方治療初髮甲狀腺功能正常橋本甲狀腺炎(HT)的臨床療效.方法 選取初髮甲狀腺功能正常 HT患者108例,按隨機數字錶法分為試驗組和對照組,各54例.對照組患者給予安慰劑治療,試驗組患者給予疏肝散結方中藥治療.結果 兩組患者用藥後甲狀腺激素促甲狀腺激素( TSH )、遊離甲狀腺素( FT4 )、遊離三碘甲狀腺原氨痠( FT3 )的含量與用藥前相比,差異無統計學意義( P>0. 05);試驗組患者的促甲狀腺受體抗體( TRAb )含量為(0. 78 ± 0. 26)U/mL、抗甲狀腺毬蛋白抗體( TGAb )為(259. 69 ± 84. 73)U/mL、抗甲狀腺過氧化物酶抗體( TPOAb )為(217. 67 ± 72. 45)U/mL,均明顯優于對照組患者的(1. 93 ± 0. 45)U/mL、(406. 34 ± 125. 65)U/mL和(365. 23 ± 101. 74)U/mL( P<0. 05 );試驗組患者的有效率為70. 37%,顯著優于對照組患者的35. 19%( P<0. 05).結論 疏肝散結方治療初髮甲狀腺功能正常HT患者效果顯著,值得臨床推廣.
목적 탐토소간산결방치료초발갑상선공능정상교본갑상선염(HT)적림상료효.방법 선취초발갑상선공능정상 HT환자108례,안수궤수자표법분위시험조화대조조,각54례.대조조환자급여안위제치료,시험조환자급여소간산결방중약치료.결과 량조환자용약후갑상선격소촉갑상선격소( TSH )、유리갑상선소( FT4 )、유리삼전갑상선원안산( FT3 )적함량여용약전상비,차이무통계학의의( P>0. 05);시험조환자적촉갑상선수체항체( TRAb )함량위(0. 78 ± 0. 26)U/mL、항갑상선구단백항체( TGAb )위(259. 69 ± 84. 73)U/mL、항갑상선과양화물매항체( TPOAb )위(217. 67 ± 72. 45)U/mL,균명현우우대조조환자적(1. 93 ± 0. 45)U/mL、(406. 34 ± 125. 65)U/mL화(365. 23 ± 101. 74)U/mL( P<0. 05 );시험조환자적유효솔위70. 37%,현저우우대조조환자적35. 19%( P<0. 05).결론 소간산결방치료초발갑상선공능정상HT환자효과현저,치득림상추엄.
Objective To investigate the clinical curative efficacy of Shugan Sanjie Prescription in treating primary thyroid function of Hashimoto's thyroiditis ( HT ) patients. Methods A total of 108 cases of primary thyroid function in Hashimoto's thyroiditis patients in the hospital diagnosed by clinical and laboratory examination and treatment were divided into two groups using random number table method,54 cases in each group. The control group was treated with placebo;the experimental group was treated with Chinese medicine treatment of Shugan Sanjie Decoction. Results After treatment, the thyroid hormone content of TSH, FT4, FT3 between two groups showed no significant change ( P > 0. 05 ); TRAb ( 0. 78 ± 0. 26 ) U/mL, TGAb ( 259. 69 ± 84. 73 ) U/mL, TPOAb ( 217. 67 ± 72. 45 ) U/mL of the experimental group was significantly better than TRAb ( 1. 93 ± 0. 45 ) U/mL, TGAb ( 406. 34 ± 125. 65 ) U/mL, TPOAb ( 365. 23 ± 101. 74 ) U/mL of the control group ( P < 0. 05 ); The clinical effective rate ( 70. 37% ) of the experimental group were significantly better than the clinical efficiency ( 35. 19%) of the control group ( P < 0. 05 ) . Conclusion Shugan Sanjie Decoction in treating patients with primary thyroid function of normal HT has remarkable effect, and it is worthy of clinical promation.
